{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:12:47Z","timestamp":1773832367917,"version":"3.50.1"},"reference-count":120,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chem. Pharm. Bull.","CHEMICAL &amp; PHARMACEUTICAL BULLETIN"],"published-print":{"date-parts":[[2024,7,1]]},"DOI":"10.1248\/cpb.c23-00416","type":"journal-article","created":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T22:17:45Z","timestamp":1719785865000},"page":"610-617","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Pipelines for Alzheimer\u2019s Disease Psychosis and Agitation"],"prefix":"10.1248","volume":"72","author":[{"given":"Takuya","family":"Oguma","sequence":"first","affiliation":[{"name":"Laboratory for Medicinal Chemistry Research, Shionogi Pharmaceutical Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Jino","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery &amp; Disease Research, Shionogi Pharmaceutical Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Chan D. C., Kasper J. D., Black B. S., Rabins P. V., <i>J. Gerontol. A Biol. Sci. Med. Sci.<\/i>, <b>58<\/b>, M548\u2013M554 (2003).","DOI":"10.1093\/gerona\/58.6.M548"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Shin I.-S., Carter M., Masterman D., Fairbanks L., Cummings J. L., <i>Am. J. Geriatr. Psychiatry<\/i>, <b>13<\/b>, 469\u2013474 (2005).","DOI":"10.1097\/00019442-200506000-00005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Schneider L. S., Dagerman K. S., <i>J. Psychiatr. Res.<\/i>, <b>38<\/b>, 105\u2013111 (2004).","DOI":"10.1016\/S0022-3956(03)00092-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ismail Z., Creese B., Aarsland D., Kales H. C., Lyketsos C. G., Sweet R. A., Ballard C., <i>Nat. Rev. Neurol.<\/i>, <b>18<\/b>, 131\u2013144 (2022).","DOI":"10.1038\/s41582-021-00597-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Jones E., Aigbogun M. S., Pike J., Berry M., Houle C. R., Husbands J., <i>J. Alzheimers Dis.<\/i>, <b>83<\/b>, 89\u2013101 (2021).","DOI":"10.3233\/JAD-210105"},{"key":"6","unstructured":"6) World Health Organization, \u201cDementia.\u201d: \u2039https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia\u203a, cited 25 January, 2024."},{"key":"7","unstructured":"7) Iwatsubo T., Niimi Y., Akiyama H., <i>J. Prev. Alzheimers Dis.<\/i>, <b>8<\/b>, 462\u2013464 (2021)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ropacki S. A., Jeste D. V., <i>Am. J. Psychiatry<\/i>, <b>162<\/b>, 2022\u20132030 (2005).","DOI":"10.1176\/appi.ajp.162.11.2022"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ballard C., Kales H. C., Lyketsos C., Aarsland D., Creese B., Mills R., Williams H., Sweet R. A., <i>Curr. Neurol. Neurosci. Rep.<\/i>, <b>20<\/b>, 57 (2020).","DOI":"10.1007\/s11910-020-01074-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Senanarong V., Cummings J. L., Fairbanks L., Mega M., Masterman D. M., O\u2019connor S. M., Stickland T. L., <i>Dement. Geriatr. Cogn. Disord.<\/i>, <b>17<\/b>, 14\u201320 (2004).","DOI":"10.1159\/000074080"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Anor C. J., O\u2019Connor S., Saund A., Tang-Wai D. F., Keren R., Tartaglia M. C., <i>Neurodegener. Dis.<\/i>, <b>17<\/b>, 127\u2013134 (2017).","DOI":"10.1159\/000455127"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Li Y. Q., Yin Z. H., Zhang X. Y., Chen Z. H., Xia M. Z., Ji L. X., Liang F. R., <i>Front. Psychiatry<\/i>, <b>13<\/b>, 1039752 (2022).","DOI":"10.3389\/fpsyt.2022.1039752"},{"key":"13","unstructured":"13) M\u00fchlbauer V., M\u00f6hler R., Dichter M. N., Zuidema S. U., K\u00f6pke S., Luijendijk H. J., <i>Cochrane Database Syst. Rev.<\/i>, <b>12<\/b>, CD013304 (2021)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Carrarini C., Russo M., Dono F., Barbone F., Rispoli M. G., Ferri L., Di Pietro M., Digiovanni A., Ajdinaj P., Speranza R., Granzotto A., Frazzini V., Thomas A., Pilotto A., Padovani A., Onofrj M., Sensi S. L., Bonanni L., <i>Front. Neurol.<\/i>, <b>12<\/b>, 644317 (2021).","DOI":"10.3389\/fneur.2021.644317"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ohno Y., Kunisawa N., Shimizu S., <i>Front. Pharmacol.<\/i>, <b>10<\/b>, 1045 (2019).","DOI":"10.3389\/fphar.2019.01045"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Schneider L. S., Tariot P. N., Dagerman K. S., Davis S. M., Hsiao J. K., Ismail M. S., Lebowitz B. D., Lyketsos C. G., Ryan J. M., Stroup T. S., Sultzer D. L., Weintraub D., Lieberman J. A., <i>N. Engl. J. Med.<\/i>, <b>355<\/b>, 1525\u20131538 (2006).","DOI":"10.1056\/NEJMoa061240"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Tampi R. R., Tampi D. J., Balachandran S., Srinivasan S., <i>Ther. Adv. Chronic Dis.<\/i>, <b>7<\/b>, 229\u2013245 (2016).","DOI":"10.1177\/2040622316658463"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Cummings J., Lee G., Nahed P., Kambar M. E. Z. N., Zhong K., Fonseca J., Taghva K., <i>Alzheimers Dement.<\/i> (N. Y.), <b>8<\/b>, e12295 (2022).","DOI":"10.1002\/trc2.12295"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Rodda J., Morgan S., Walker Z., <i>Int. Psychogeriatr.<\/i>, <b>21<\/b>, 813\u2013824 (2009).","DOI":"10.1017\/S1041610209990354"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Vasiliu O., <i>Front. Psychiatry<\/i>, <b>13<\/b>, 1069432 (2022).","DOI":"10.3389\/fpsyt.2022.882491"},{"key":"21","unstructured":"21) U. S. Food &amp; Drug Administration. \u201cFDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer\u2019s Disease.\u201d: \u2039https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease\u203a, cited 25 January, 2024."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Stahl S. M., <i>CNS Spectr.<\/i>, <b>21<\/b>, 1\u20136 (2016).","DOI":"10.1017\/S1092852915000954"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yunusa I., Rashid N., Demos G. N., Mahadik B. S., Abler V. C., Rajagopalan K., <i>Adv. Ther.<\/i>, <b>39<\/b>, 1993\u20132008 (2022).","DOI":"10.1007\/s12325-022-02075-8"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Streim J. E., Porsteinsson A. P., Breder C. D., Swanink R., Marcus R., McQuade R., Carson W. H., <i>Am. J. Geriatr. Psychiatry<\/i>, <b>16<\/b>, 537\u2013550 (2008).","DOI":"10.1097\/JGP.0b013e318165db77"},{"key":"25","unstructured":"25) ClinicalTrials.gov, \u201cA Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer\u2019s Agitation.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT01862640\u203a, cited 23 January, 2024."},{"key":"26","unstructured":"26) ClinicalTrials.gov, \u201cSafety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects with Agitation Associated with Dementia of the Alzheimer\u2019s Type.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT01922258\u203a, cited 23 January, 2024."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Cohen-Mansfield J., Marx M. S., Rosenthal A. S., <i>J. Gerontol.<\/i>, <b>44<\/b>, M77\u2013M84 (1989).","DOI":"10.1093\/geronj\/44.3.M77"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Grossberg G. T., Kohegyi E., Mergel V., Josiassen M. K., Meulien D., Hobart M., Slomkowski M., Baker R. A., McQuade R. D., Cummings J. L., <i>Am. J. Geriatr. Psychiatry<\/i>, <b>28<\/b>, 383\u2013400 (2020).","DOI":"10.1016\/j.jagp.2019.09.009"},{"key":"29","unstructured":"29) ClinicalTrials.gov, \u201cA Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated with Dementia of the Alzheimer\u2019s Type.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT03548584\u203a, cited 23 January, 2024."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Khoury R., Marx C., Mirgati S., Velury D., Chakkamparambil B., Grossberg G. T., <i>Expert Opin. Pharmacother.<\/i>, <b>22<\/b>, 783\u2013795 (2021).","DOI":"10.1080\/14656566.2021.1882995"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Siu A., Drachtman R., <i>CNS Drug Rev.<\/i>, <b>13<\/b>, 96\u2013106 (2007).","DOI":"10.1111\/j.1527-3458.2007.00006.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Taylor C. P., Traynelis S. F., Siffert J., Pope L. E., Matsumoto R. R., <i>Pharmacol. Ther.<\/i>, <b>164<\/b>, 170\u2013182 (2016).","DOI":"10.1016\/j.pharmthera.2016.04.010"},{"key":"33","unstructured":"33) Otsuka America Pharmaceutical, Inc., \u201cNUEDEXTA<sup>\u00ae<\/sup> (dextromethorphan HBr and quinidine sulfate) 20 mg\/10 mg capsules\u201d \u2039https:\/\/www.nuedexta.com\u203a cited 25 January, 2024."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Cummings J. L., Lyketsos C. G., Peskind E. R., Porsteinsson A. P., Mintzer J. E., Scharre D. W., De La Gandara J. E., Agronin M., Davis C. S., Nguyen U., Shin P., Tariot P. N., Siffert J., <i>JAMA<\/i>, <b>314<\/b>, 1242\u20131254 (2015).","DOI":"10.1001\/jama.2015.10214"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Khoury R., Marx C., Mirgati S., Velury D., Chakkamparambil B., Grossberg G. T., <i>Expert Opin. Pharmacother.<\/i>, <b>22<\/b>, 783\u2013795 (2021).","DOI":"10.1080\/14656566.2021.1882995"},{"key":"36","unstructured":"36) Otsuka Pharmaceutical Co, Ltd. \u201cOtsuka\u2019s Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer\u2019s Dementia\u201d \u2039https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2019\/20190325_2.html\u203a cited 25 January, 2024."},{"key":"37","unstructured":"37) Otsuka Pharmaceutical Co, Ltd. \u201cOtsuka\u2019s Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Second Phase 3 Trial Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer\u2019s Dementia\u201d \u2039https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2019\/20190927_1.html\u203a cited 25 January, 2024."},{"key":"38","unstructured":"38) ClinicalTrials.gov, \u201cAssessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]\/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer\u2019s Type.\u201d: \u2039https:\/\/clinicaltrials.gov\/study\/NCT03393520\u203a, cited 25 January, 2024."},{"key":"39","unstructured":"39) ClinicalTrials.gov, \u201cAssessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients with Dementia of the Alzheimer\u2019s Type.\u201d: \u2039https:\/\/clinicaltrials.gov\/study\/NCT04408755\u203a, cited 25 January, 2024."},{"key":"40","unstructured":"40) ClinicalTrials.gov, \u201cStudy to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients with Dementia of the Alzheimer\u2019s Type.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT04464564\u203a, cited 25 January, 2024."},{"key":"41","unstructured":"41) Otsuka Pharmaceutical Co, Ltd. \u201cOtsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia due to Alzheimer\u2019s Disease\u201d \u2039https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2024\/20240213_1.html\u203a cited 21 March, 2024."},{"key":"42","unstructured":"42) Axsome Therapeutics, Inc., \u201cAuvelity (dextromethorphane HBr and bupropion HCl) extended-release tablets 45mg\/105mg\u201d \u2039https:\/\/www.auvelity.com\u203a cited 25 January, 2024."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Stahl S. M., Pradko J. F., Haight B. R., Modell J. G., Rockett C. B., Learned-Coughlin S., <i>Prim. Care Companion J. Clin. Psychiatry<\/i>, <b>6<\/b>, 159\u2013166 (2004).","DOI":"10.4088\/PCC.v06n0403"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Ward K., Citrome L., <i>Expert Opin. Investig. Drugs<\/i>, <b>31<\/b>, 773\u2013780 (2022).","DOI":"10.1080\/13543784.2022.2096006"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Johnston A. J., Ascher J., Leadbetter R., Schmith V. D., Patel D. K., Durcan M., Bentley B., <i>Drugs<\/i>, <b>62<\/b> (Suppl. 2), 11\u201324 (2002).","DOI":"10.2165\/00003495-200262002-00002"},{"key":"46","unstructured":"46) Axsome Therapeutics, Inc., \u201cAxsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2\/3 Trial in Alzheimer\u2019s Disease Agitation\u201d \u2039https:\/\/axsometherapeuticsinc.gcs-web.com\/news-releases\/news-release-details\/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-2\u203a cited 25 January, 2024."},{"key":"47","unstructured":"47) ClinicalTrials.gov, \u201cAssessing Clinical Outcomes in Alzheimer\u2019s Disease Agitation (ACCORD)\u201d \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT04797715\u203a, cited 25 January, 2024."},{"key":"48","unstructured":"48) Axsome Therapeutics, Inc., \u201cAxsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer\u2019s Disease Agitation\u201d \u2039https:\/\/axsometherapeuticsinc.gcs-web.com\/news-releases\/news-release-details\/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-3\u203a cited 25 January, 2024."},{"key":"49","unstructured":"49) ClinicalTrials.gov, \u201cA Study to Assess the Efficacy and Safety of AXS-05 in Subjects with Alzheimer\u2019s Disease Agitation (ADVANCE-2).\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT05557409\u203a, cited 25 January, 2024."},{"key":"50","unstructured":"50) BioXcel Therapeutics, Inc., \u201cIgalmiTM (dexmedetomidine) sublingual film \u2013 120 mcg, 180 mcg\u201d \u2039https:\/\/www.igalmihcp.com\u203a cited 25 January, 2024."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Keating G. M., <i>Drugs<\/i>, <b>75<\/b>, 1119\u20131130 (2015).","DOI":"10.1007\/s40265-015-0419-5"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Gertler R., Brown H. C., Mitchell D. H., Silvius E. N., <i>Proc. Bayl. Univ. Med. Cent.<\/i>, <b>14<\/b>, 13\u201321 (2001).","DOI":"10.1080\/08998280.2001.11927725"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Sun M., Peng T., Sun Y., Huang Z., Jiang J., Wang C., Li Y., Zhang Y., Kong W., Fan L., Sun X., Zhao X., <i>Aging Clin. Exp. Res.<\/i>, <b>34<\/b>, 611\u2013618 (2022).","DOI":"10.1007\/s40520-021-01984-y"},{"key":"54","unstructured":"54) BioXcel Therapeutics, Inc., \u201cBioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer\u2019s Disease\u201d \u2039https:\/\/ir.bioxceltherapeutics.com\/news-releases\/news-release-details\/bioxcel-therapeutics-announces-first-patient-dosed-tranquility-0\u203a, cited 25 January, 2024."},{"key":"55","unstructured":"55) ClinicalTrials.gov, \u201cDexmedetomidine in the Treatment of Agitation Associated with Dementia (TRANQUILITY III).\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT05665088\u203a, cited 25 January, 2024."},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Hyttel J., B\u00f8ges\u00f8 K. P., Perregaard J., S\u00e1nchez C., <i>J. Neural Transm.<\/i> (Vienna), <b>88<\/b>, 157\u2013160 (1992).","DOI":"10.1007\/BF01244820"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Chakraborty S., Lennon J. C., Malkaram S. A., Zeng Y., Fisher D. W., Dong H., <i>Neurosci. Lett.<\/i>, <b>704<\/b>, 36\u201344 (2019).","DOI":"10.1016\/j.neulet.2019.03.050"},{"key":"58","unstructured":"58) ClinicalTrials.gov, \u201cCitalopram for Agitation in Alzheimer\u2019s Disease (CitAD).\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT00898807\u203a, cited 25 January, 2024."},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Porsteinsson A. P., Drye L. T., Pollock B. G., Devanand D. P., Frangakis C., Ismail Z., Marano C., Meinert C. L., Mintzer J. E., Munro C. A., Pelton G., Rabins P. V., Rosenberg P. B., Schneider L. S., Shade D. M., Weintraub D., Yesavage J., Lyketsos C. G., <i>JAMA<\/i>, <b>311<\/b>, 682\u2013691 (2014).","DOI":"10.1001\/jama.2014.93"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Ehrhardt S., Porsteinsson A. P., Munro C. A., Rosenberg P. B., Pollock B. G., Devanand D. P., Mintzer J., Rajji T. K., Ismail Z., Schneider L. S., Baksh S. N., Drye L. T., Avramopoulos D., Shade D. M., Lyketsos C. G., <i>Alzheimers Dement.<\/i>, <b>15<\/b>, 1427\u20131436 (2019).","DOI":"10.1016\/j.jalz.2019.06.4946"},{"key":"61","unstructured":"61) ClinicalTrials.gov, \u201cEscitalopram for Agitation in Alzheimer\u2019s Disease (S-CitAD).\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT03108846\u203a, cited 25 January, 2024."},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Volicer L., Stelly M., Morris J., McLaughlin J., Volicer B. J., <i>Int. J. Geriatr. Psychiatry<\/i>, <b>12<\/b>, 913\u2013919 (1997).","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Woodward M. R., Harper D. G., Stolyar A., Forester B. P., Ellison J. M., <i>Am. J. Geriatr. Psychiatry<\/i>, <b>22<\/b>, 415\u2013419 (2014).","DOI":"10.1016\/j.jagp.2012.11.022"},{"key":"64","unstructured":"64) ClinicalTrials.gov, \u201cDelta-THC in Behavioral Disturbances in Dementia.\u201d: \u2039https:\/\/clinicaltrials.gov\/study\/NCT01302340\u203a, cited 25 January, 2024."},{"key":"65","unstructured":"65) ClinicalTrials.gov, \u201cDelta-THC in Dementia.\u201d: \u2039https:\/\/clinicaltrials.gov\/study\/NCT01608217\u203a, cited 25 January, 2024."},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) van den Elsen G. A., Ahmed A. I., Verkes R. J., Kramers C., Feuth T., Rosenberg P. B., van der Marck M. A., Olde Rikkert M. G., <i>Neurology<\/i>, <b>84<\/b>, 2338\u20132346 (2015).","DOI":"10.1212\/WNL.0000000000001675"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) van den Elsen G. A., Tobben L., Ahmed A. I., Verkes R. J., Kramers C., Marijnissen R. M., Olde Rikkert M. G., van der Marck M. A., <i>J. Psychopharmacol.<\/i>, <b>31<\/b>, 184\u2013191 (2017).","DOI":"10.1177\/0269881116665357"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Charernboon T., Lerthattasilp T., Supasitthumrong T., <i>Clin. Gerontol.<\/i>, <b>44<\/b>, 16\u201324 (2021).","DOI":"10.1080\/07317115.2020.1742832"},{"key":"69","unstructured":"69) ClinicalTrials.gov, \u201cTrial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer\u2019s Disease (THC-AD).\u201d: \u2039https:\/\/clinicaltrials.gov\/study\/NCT02792257\u203a, cited 20 January, 2024."},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Cohen L. M., Ash E., Outen J. D., Vandrey R., Amjad H., Agronin M., Burhanullah M. H., Walsh P., Wilkins J. M., Leoutsakos J. M., Nowrangi M. A., Harper D., Rosenberg P. B., Forester B. P., <i>Int. Psychogeriatr.<\/i>, 1\u20136 (2021).","DOI":"10.1017\/S1041610221001150"},{"key":"71","unstructured":"71) ClinicalTrials.gov, \u201cSCI-110 for Alzheimer Disease and Agitation.\u201d: \u2039https:\/\/clinicaltrials.gov\/study\/NCT05239390\u203a, cited 20 January, 2024."},{"key":"72","unstructured":"72) Global Newswire, \u201cSciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer\u2019s Agitation.\u201d: \u2039https:\/\/www.globenewswire.com\/en\/news-release\/2023\/11\/15\/2781004\/0\/en\/SciSparc-Celebrates-Major-Breakthrough-Positive-Results-Show-its-Treatment-has-a-Remarkable-Impact-on-Alzheimer-s-Agitation.html\u203a, cited 21 January, 2024."},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Arbelaez M. J., Gutierrez E., Sanchez L. T., Tangarife M. A., Delgado-Murillo L., Rodriguez-Soacha D., Shahnawaz S. S., Ghazaryan V., Naranjo M. P., Venegas M., Garcia D. S., Pujals K. Y., De Jesus W. J., Grimaldi C., Lanct\u00f4t K. L., Hong L. E., Mukunda R., <i>Alzheimers Dement.<\/i>, <b>19<\/b> (S21), e079813 (2023).","DOI":"10.1002\/alz.079813"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Silva-Garc\u00eda D., Gutierrez E., Sanchez L. T., Arbelaez M. J., Tangarife M. A., Delgado-Murillo L., Rodriguez-Soacha D., Shahnawaz S. S., Ghazaryan V., Naranjo M. P., Venegas M., Pujals K. Y., De Jesus W. J., Grimaldi C., Lanct\u00f4t K. L., Hong L. E., Mukunda R., <i>Alzheimers Dement.<\/i>, <b>19<\/b> (S21), e080273 (2023).","DOI":"10.1002\/alz.080273"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Grossman E., <i>Hypertens. Res.<\/i>, <b>36<\/b>, 682\u2013683 (2013).","DOI":"10.1038\/hr.2013.29"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Hadi A., Ghaedi E., Moradi S., Pourmasoumi M., Ghavami A., Kafeshani M., <i>Horm. Metab. Res.<\/i>, <b>51<\/b>, 157\u2013164 (2019).","DOI":"10.1055\/a-0841-6638"},{"key":"77","unstructured":"77) ClinicalTrials.gov, \u201cStudy of IGC-AD1 in Subjects with Dementia Due to Alzheimer\u2019s Disease.\u201d: \u2039https:\/\/clinicaltrials.gov\/study\/NCT04749563\u203a, cited 23 January, 2024."},{"key":"78","unstructured":"78) ClinicalTrials.gov, \u201cIGC-AD1 Trial on Agitation in Dementia Due to Alzheimer\u2019s (IGC-AD1-P2).\u201d: \u2039https:\/\/clinicaltrials.gov\/study\/NCT05543681\u203a, cited 23 January, 2024."},{"key":"79","unstructured":"79) Pharma I. G. C., \u201cIGC Pharma Activates ClinCloud, One Of 12 Sites In Ongoing Phase 2b Alzheimer\u2019s Trial\u201d \u2039https:\/\/investor.igcpharma.com\/igc-pharma-activates-clincloud-one\u203a cited 23 January, 2024."},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Walsh Z., Gonzalez R., Crosby K., Thiessen M. S., Chris C., Bonn-Miller M. O., <i>Clin. Psychol. Rev.<\/i>, <b>51<\/b>, 15\u201329 (2017).","DOI":"10.1016\/j.cpr.2016.10.002"},{"key":"81","unstructured":"81) ClinicalTrials.gov, \u201cSafety and Efficacy of Nabilone in Alzheimer\u2019s Disease\u201d \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT02351882\u203a cited 25 January, 2024."},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Herrmann N., Ruthirakuhan M., Gallagher D., Verhoeff N. P. L. G., Kiss A., Black S. E., Lanct\u00f4t K. L., <i>Am. J. Geriatr. Psychiatry<\/i>, <b>27<\/b>, 1161\u20131173 (2019).","DOI":"10.1016\/j.jagp.2019.05.002"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Ruthirakuhan M. T., Herrmann N., Gallagher D., Andreazza A. C., Kiss A., Verhoeff N. P. L. G., Black S. E., Lanct\u00f4t K. L., <i>Contemp. Clin. Trials Commun.<\/i>, <b>15<\/b>, 100385 (2019).","DOI":"10.1016\/j.conctc.2019.100385"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Mead A., <i>Front. Plant Sci.<\/i>, <b>10<\/b>, 697 (2019).","DOI":"10.3389\/fpls.2019.00697"},{"key":"85","unstructured":"85) ClinicalTrials.gov, \u201cNabilone for Agitation Blinded Intervention Trial (NAB-IT).\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT04516057\u203a, cited 25 January, 2024."},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Cavero I., Roach A. G., <i>Life Sci.<\/i>, <b>27<\/b>, 1525\u20131540 (1980).","DOI":"10.1016\/0024-3205(80)90561-5"},{"key":"87","unstructured":"87) Elrod R., Peskind E. R., DiGiacomo L., Brodkin K. I., Veith R. C., Raskind M. A., <i>Am. J. Psychiatry<\/i>, <b>154<\/b>, 25\u201330 (1997)."},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Szot P., White S. S., Greenup J. L., Leverenz J. B., Peskind E. R., Raskind M. A., <i>J. Neurosci.<\/i>, <b>26<\/b>, 467\u2013478 (2006).","DOI":"10.1523\/JNEUROSCI.4265-05.2006"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Tampi R. R., Tampi D. J., Farheen S. A., Adnan M., Dasarathy D., <i>Drugs Context<\/i>, <b>11<\/b>, 1\u201311 (2022).","DOI":"10.7573\/dic.2022-8-3"},{"key":"90","unstructured":"90) ClinicalTrials.gov, \u201cAlzheimer\u2019s in Long-Term Care\u2014Treatment for Agitation.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT00161473\u203a, cited 18 January, 2024."},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Wang L. Y., Shofer J. B., Rohde K., Hart K. L., Hoff D. J., McFall Y. H., Raskind M. A., Peskind E. R., <i>Am. J. Geriatr. Psychiatry<\/i>, <b>17<\/b>, 744\u2013751 (2009).","DOI":"10.1097\/JGP.0b013e3181ab8c61"},{"key":"92","unstructured":"92) ClinicalTrials.gov, \u201cPrazosin Treatment for Disruptive Agitation in Alzheimer\u2019s Disease.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT01126099\u203a, cited 18 January, 2024."},{"key":"93","unstructured":"93) ClinicalTrials.gov, \u201cPrazosin for Agitation in Alzheimer\u2019s Disease.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT03710642\u203a, cited 18 January, 2024."},{"key":"94","unstructured":"94) Acadia Pharmaceuticals Inc, \u201cNUPLAZID<sup>\u00ae<\/sup> (pimavanserin) 34mg capsules\u201d \u2039https:\/\/www.nuplazid.com\u203a cited 25 January, 2024."},{"key":"95","unstructured":"95) Cruz M. P., <i>Pharm. Ther.<\/i>, <b>42<\/b>, 368\u2013371 (2017)."},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Abler V., Brain C., Ballard C., Berrio A., Coate B., Espay A. J., <i>Front. Neurol.<\/i>, <b>13<\/b>, 919778 (2022).","DOI":"10.3389\/fneur.2022.919778"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Cummings J., Isaacson S., Mills R., Williams H., Chi-Burris K., Corbett A., Dhall R., Ballard C., <i>Lancet<\/i>, <b>383<\/b>, 533\u2013540 (2014).","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Espay A. J., Guskey M. T., Norton J. C., Coate B., Vizcarra J. A., Ballard C., Factor S. A., Friedman J. H., Lang A. E., Larsen N. J., Andersson C., Fredericks D., Weintraub D., <i>Mov. Disord.<\/i>, <b>33<\/b>, 1769\u20131776 (2018).","DOI":"10.1002\/mds.27488"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Ballard C., Banister C., Khan Z., <i>et al.<\/i>, <i>Lancet Neurol.<\/i>, <b>17<\/b>, 213\u2013222 (2018).","DOI":"10.1016\/S1474-4422(18)30039-5"},{"key":"100","unstructured":"100) ClinicalTrials.gov, \u201cA Study of the Safety and Efficacy of Pimavanserin in Patients with Alzheimer\u2019s Disease Psychosis.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT02035553\u203a, cited 25 January, 2024."},{"key":"101","unstructured":"101) ClinicalTrials.gov, \u201cRelapse Prevention Study of Pimavanserin in Dementia-related Psychosis.\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT03325556\u203a, cited 25 January, 2024."},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Tariot P. N., Cummings J. L., Soto-Martin M. E., Ballard C., Erten-Lyons D., Sultzer D. L., Devanand D. P., Weintraub D., McEvoy B., Youakim J. M., Stankovic S., Foff E. P., <i>N. Engl. J. Med.<\/i>, <b>385<\/b>, 309\u2013319 (2021).","DOI":"10.1056\/NEJMoa2034634"},{"key":"103","unstructured":"103) Acadia Pharmaceuticals Inc, \u201cAcadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis\u201d \u2039https:\/\/acadia.com\/media\/news-releases\/acadia-pharmaceuticals-receives-complete-response-letter-from-u-s-fda-for-supplemental-new-drug-application-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-dementia\u203a, cited 25 January, 2024."},{"key":"104","unstructured":"104) Acadia Pharmaceuticals Inc, \u201cAcadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer\u2019s Disease Psychosis\u201d \u2039https:\/\/acadia.com\/media\/news-releases\/acadia-pharmaceuticals-receives-complete-response-letter-from-u-s-fda-for-supplemental-new-drug-application-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-alzheime\u203a, cited 25 January, 2024."},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Ward J. S., Merritt L., Klimkowski V. J., Lamb M. L., Mitch C. H., Bymaster F. P., Sawyer B., Shannon H. E., Olesen P. H., <i>J. Med. Chem.<\/i>, <b>35<\/b>, 4011\u20134019 (1992).","DOI":"10.1021\/jm00100a005"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Bymaster F. P., Whitesitt C. A., Shannon H. E., DeLapp N., Ward J. S., Calligaro D. O., Shipley L. A., Buelke-Sam J. L., Bodick N. C., Farde L., Sheardown M. J., Olesen P. H., Hansen K. T., Suzdak P. D., Swedberg M. D. B., Sauerberg P., Mitch C. H., <i>Drug Dev. Res.<\/i>, <b>40<\/b>, 158\u2013170 (1997).","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.3.CO;2-6"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Bodick N. C., Offen W. W., Levey A. I., Cutler N. R., Gauthier S. G., Satlin A., Shannon H. E., Tollefson G. D., Rasmussen K., Bymaster F. P., Hurley D. J., Potter W. Z., Paul S. M., <i>Arch. Neurol.<\/i>, <b>54<\/b>, 465\u2013473 (1997).","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Breier A., Brannan S. K., Paul S. M., Miller A. C., <i>Psychopharmacology<\/i> (Berl.), <b>240<\/b>, 1191\u20131198 (2023).","DOI":"10.1007\/s00213-023-06362-2"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Brannan S., Sawchak S., Miller A., Paul S. M., Breier A., <i>Biol. Psychiatry<\/i>, <b>87<\/b>, S169 (2020).","DOI":"10.1016\/j.biopsych.2020.02.446"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Brannan S. K., Sawchak S., Miller A. C., Lieberman J. A., Paul S. M., Breier A., <i>N. Engl. J. Med.<\/i>, <b>384<\/b>, 717\u2013726 (2021).","DOI":"10.1056\/NEJMoa2017015"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Sauder C., Allen L. A., Baker E., Miller A. C., Paul S. M., Brannan S. K., <i>Transl. Psychiatry<\/i>, <b>12<\/b>, 491 (2022).","DOI":"10.1038\/s41398-022-02254-9"},{"key":"112","unstructured":"112) ClinicalTrials.gov, \u201cA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated with Alzheimer\u2019s Disease Dementia (ADEPT-1).\u201d: \u2039https:\/\/www.clinicaltrials.gov\/study\/NCT05511363\u203a, cited 25 January, 2024."},{"key":"113","unstructured":"113) KARUNA Therapeutics, \u201cKaruna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates\u201d \u2039https:\/\/investors.karunatx.com\/news-releases\/news-release-details\/karuna-therapeutics-reports-third-quarter-2023-financial-results\u203a, cited 25 January, 2024."},{"key":"114","unstructured":"114) Acadia Pharmaceuticals Inc, \u201cProduct Pipeline\u201d \u2039https:\/\/acadia.com\/pipeline\/\u203a, cited 25 January 2024."},{"key":"115","unstructured":"115) Exscientia \u201cExscientia announces second molecule created using AI from Sumitomo Dainippon Pharma collaboration to enter Phase 1 clinical trial.\u201d \u2039https:\/\/investors.exscientia.ai\/press-releases\/press-release-details\/2021\/exscientia-announces-second-molecule-created-using-ai-from-sumitomo-dainippon-pharma-collaboration-to-enter-phase-1-clinical-trial\/Default.aspx\u203a, cited 25 January, 2024."},{"key":"116","unstructured":"116) Intra-Cellular Therapies, Inc., \u201cIntra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284\u201d \u2039https:\/\/ir.intracellulartherapies.com\/news-releases\/news-release-details\/intra-cellular-therapies-announces-expansion-its-pipeline\u203a, cited 25 January, 2024."},{"key":"117","unstructured":"117) Edinoff A., Wu N., deBoisblanc C., Feltner C. O., Norder M., Tzoneva V., Kaye A. M., Cornett E. M., Kaye A. D., Viswanath O., Urits I., <i>Psychopharmacol. Bull.<\/i>, <b>50<\/b>, 32\u201359 (2020)."},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Snyder G. L., Vanover K. E., Zhu H., Miller D. B., O\u2019Callaghan J. P., Tomesch J., Li P., Zhang Q., Krishnan V., Hendrick J. P., Nestler E. J., Davis R. E., Wennogle L. P., Mates S., <i>Psychopharmacology<\/i> (Berl.), <b>232<\/b>, 605\u2013621 (2015).","DOI":"10.1007\/s00213-014-3704-1"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Pankevich D. E., Altevogt B. M., Dunlop J., Gage F. H., Hyman S. E., <i>Neuron<\/i>, <b>84<\/b>, 546\u2013553 (2014).","DOI":"10.1016\/j.neuron.2014.10.007"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Santiago J. A., Potashkin J. A., <i>Front. Aging Neurosci.<\/i>, <b>13<\/b>, 631770 (2021).","DOI":"10.3389\/fnagi.2021.631770"}],"container-title":["Chemical and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpb\/72\/7\/72_c23-00416\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T03:31:35Z","timestamp":1720236695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpb\/72\/7\/72_c23-00416\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":120,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/cpb.c23-00416","relation":{},"ISSN":["0009-2363","1347-5223"],"issn-type":[{"value":"0009-2363","type":"print"},{"value":"1347-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"c23-00416"}}